Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed yesterday at $29.98.
According to TipRanks, Goonewardene is a 3-star analyst with an average return of 5.5% and a 36.97% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Genmab, and Compugen.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genmab with a $39.58 average price target.
GMAB market cap is currently $19.92B and has a P/E ratio of 30.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genmab (GMAB) Company Description:
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
